新学期临近，对于许多杭州的初二女生和家长来说，这个寒假除了走亲访友、体育锻炼、参与实践 等，还多了一件关乎健康的"大事"——接种国家免疫规划提供的免费双价HPV疫苗。 "很多家长关心为什么要这么早给孩子接种？"专家提到，研究显示，我国女性HPV感染的第一个高 峰为17—24岁，且近年来宫颈癌发病日益年轻化，最小发病年龄已低至15岁。因此在感染高峰到来前接 种疫苗建立保护屏障至关重要，"9—14岁女孩仅需接种两剂次，就能达到很好的保护效果，实现'早接 种、早保护'。" 记者了解到，除了国家免疫规划提供的免费双价HPV疫苗外，适龄女生也可自愿、自费选择其他不 同品牌、不同价型的HPV疫苗进行替代接种。 对于想要选择九价疫苗的家长和孩子来说，眼下也是一个不错的窗口期。目前，上城区、拱墅区、 西湖区、萧山区、余杭区、富阳区、桐庐县、建德市、淳安县等地正在开展HPV疫苗接种惠民活动，9- 14岁女生全程接种两剂次（按0、6月接种）进口九价HPV疫苗可享"减免1剂次疫苗费用"；预计临安区 和钱塘区将于3月1日开始。家长可选择居住地或学校所在的社区卫生服务中心预防接种门诊进行接种， 建议提前通过浙里办App上的"浙里接种" ...

浙江省金华市人民医院新生儿科护士在护理新生儿（资料图片）。 新华社发（时宽兵 摄） 提供心理、健康体重管理门诊服务 一名女士在复旦大学附属妇产科医院接种九价HPV疫苗（资料图片）。 新华社记者 刘颖 摄 2月10日，在国家卫生健康委今年新闻发布会新增的"中医养生保健动作推荐"环节上，中国中医科学院 西苑医院主治医师谭天阳展示八段锦中的动作。 新华社记者 张玉薇 摄 ●新华社记者 李恒 徐鹏航 看病就医，事关千家万户。2026年卫生健康系统为民服务十件实事项目前不久公布，包括心理门诊服 务、健康体重管理门诊服务、疫苗接种服务等。国家卫生健康委近日举行新闻发布会，介绍这些实事将 如何落实。 提升儿科服务能力、加强早孕关爱门诊服务 截至2025年底，全国4845家二级、三级公立综合医院可提供儿科服务，4万家乡镇卫生院和社区卫生服 务中心可提供儿童常见病、多发病诊疗服务。 国家卫生健康委基层司司长焦雅辉介绍，2026年将进一步扩大基层儿科诊疗服务，新增1000家乡镇卫生 院和社区卫生服务中心提供儿科诊疗服务，鼓励有条件的基层医疗卫生机构设置独立儿科，开展周末门 诊服务等。 国家卫生健康委从2025年起实施早孕关爱行动 ...

（来源：廊坊日报） 转自：廊坊日报 本报讯（记者 郑爽 通讯员 任蕊）日前，家住安次区豪邸坊小区的居民刘女士，带着刚满13岁的女儿免 费接种HPV疫苗，"孩子一放寒假就带她来打了，整个过程高效方便。" 为保障儿童青少年健康成长，根据国家疾控局等七部门印发的《关于将人乳头瘤病毒疫苗纳入国家免疫 规划有关工作事宜的通知》要求，自2025年11月10日起，全国范围内为2011年11月10日以后出生的满13 周岁女孩，免费接种2剂次双价HPV疫苗。 世界卫生组织（WHO）推荐，9~14岁女孩是HPV疫苗接种的首要人群。HPV主要通过性行为感染，在 感染风险显著增加之前（即发生性行为年龄之前）接种，能获得最佳的保护效果，实现"早接种，早保 护"。同时大量数据表明，这个年龄段接种能够获得最佳的预防效果，是最及时、最经济、最有效的保 护措施。基于充分的科学论证和国际经验，我国确定了该防护策略。 接种对象：2011年11月10日以后出生年满13周岁的女孩。 接种程序：接种2剂次双价HPV疫苗，间隔6个月。已完成其他HPV疫苗（包括双价、四价或九价）全程 接种的孩子无需重复接种。 工作人员表示，我市除免疫规划双价HPV疫苗免费 ...

证券日报网讯2月13日，万泰生物（603392）在互动平台回答投资者提问时表示，股价波动受到宏观经 济、行业周期、市场情绪等多重复杂因素的共同影响。公司九价HPV疫苗在与进口疫苗的"头对头"临床 试验中，证实免疫原性与安全性相当，同时公司严格执行高标准的质量管理体系，保障了产品的安全有 效和均一稳定。自公司九价HPV疫苗上市以来，接种工作正在全国平稳、有序推进。 ...

Core Insights - 2025 marks a milestone year for China's innovative pharmaceuticals, with a significant increase in the number of approved drugs and vaccines, driven by supportive policies, international expansion, and expedited review processes [1][2] Group 1: Drug Approvals and Market Trends - In 2025, China approved 76 innovative drugs, surpassing the 48 approved in 2024, setting a historical record [1] - The number of approved innovative drugs in China exceeded that of the US FDA, which approved 46 new drugs in the same year [1] - China saw the approval of 11 First-in-class drugs, with 4 being independently developed domestically [1] - The total value of licensing transactions for innovative drugs exceeded $130 billion, with over 150 deals made, marking another historical high [1] Group 2: Breakthrough Therapies and Innovations - Among the 76 approved drugs, 17 were recognized as breakthrough therapies, with 13 focused on oncology [2] - Notable drug launches included the first stem cell therapy in China, marking a historic breakthrough in stem cell treatment [2] - The launch of targeted HER2 drugs for non-small cell lung cancer and cholangiocarcinoma signifies a new phase in precision treatment for solid tumors in China [2] Group 3: Disease-Specific Developments - In oncology, 34 new drugs were approved, with breast cancer treatments leading at 9 new drugs, followed by 6 for lung cancer and 8 for hematological malignancies [3] - Two CAR-T cell therapies targeting CD19 were approved, bringing the total number of domestic CAR-T therapies to 7 [3] Group 4: Innovations in Other Therapeutic Areas - In the influenza treatment sector, four new drugs were launched, addressing public health needs during peak flu seasons [4] - The innovative vaccine sector saw significant advancements, including the launch of China's first nine-valent HPV vaccine and a 13-valent pneumococcal conjugate vaccine [5] - The emergence of a serum-free rabies vaccine is expected to fill a market gap, showcasing China's growing capabilities in biopharmaceutical innovation [5]

Group 1 - The core viewpoint of the article is that Watson Bio (300142) is currently in the Phase III clinical research stage for its nine-valent HPV vaccine [1] - The company stated that updates regarding the vaccine's development progress should be based on announcements disclosed by the company [1]

Core Viewpoint - Watson Bio's HPV vaccine is expected to benefit significantly from the inclusion of the bivalent HPV vaccine in the national immunization program starting November 2025, with Yunnan province already implementing a free vaccination policy, indicating substantial growth potential for the company's HPV vaccine sales [1] Group 1: Production Capacity and Expansion Plans - The company is currently assessing whether its HPV vaccine production capacity can meet the market demand set by the national immunization program and is considering expansion plans [1] - The company emphasizes that the final procurement results will depend on negotiations with provincial disease control centers, and further contracts will need to be signed for production and supply [1] Group 2: Clinical Progress and Market Strategy - Watson Bio's nine-valent HPV vaccine is currently in Phase III clinical trials, and any significant progress in the development of its vaccines will be disclosed in a timely manner [1] - The company aims to leverage the supportive policies in Yunnan's biopharmaceutical sector to accelerate the market entry of its high-priced HPV vaccine [1] Group 3: Sales Growth Targets - The company has not disclosed specific sales growth targets for its HPV vaccine for 2026, indicating that further information will be provided as it becomes available [1]

Group 1 - The core point of the article is that Watson Bio is currently in the III phase of clinical research for its nine-valent HPV vaccine and will disclose any substantial and phase-related progress in its vaccine development in a timely manner [2]

格隆汇2月10日丨沃森生物(300142.SZ)在投资者互动平台表示，公司九价HPV疫苗目前处于III期临床研 究阶段。 ...

证券日报网讯 2月5日，万泰生物在互动平台回答投资者提问时表示，截至目前，公司九价HPV疫苗已 完成吉林省的准入，贵州省的准入按贵州省疾病预防控制中心的工作计划推进中。 （文章来源：证券日报） ...